Kyverna Therapeutics, Inc.
NASDAQ:KYTXBiotechnology
-$0.12 today
- Market cap
- $283.23M
- Beta
- 1.96
- P/E (TTM)
- -3.1
- EPS (TTM)
- -$2.59
Volume 1.05M
Average 0.94M
KYTX Weighted Avg Shares (Diluted)
Average shares outstanding including dilutive securities, used to calculate diluted EPS.
Kyverna Therapeutics, Inc.NASDAQ: KYTX
Weighted Avg Shares (Diluted) · Q1 FY2026 · quarter ended Mar 2026
Weighted avg shares (diluted) growth accelerates
Q1 FY2026 weighted avg shares (diluted) of 60.43M shares rose 39.8% year over year, ahead of the +12.5% change in trailing-twelve-month weighted avg shares (diluted). Sequentially, it rose 28.2% from the prior quarter. Over 3 fiscal years it compounded at +19.7% a year.
Context
- Weighted avg shares (diluted) increased in 2 of the last 3 fiscal years.
What to watch
Whether quarterly growth of +39.8% holds above the trailing-twelve-month pace of +12.5%.
Sources:Income StatementText generated from reported figures; not investment advice.
Weighted Avg Shares (Diluted) history
Shares · from the income statement
- Latest · FY2025
- 44.26M USD
- Year-over-year change
- +15.5%
- 4-year CAGR
- +14.4%
| Period | Period end | Weighted Avg Shares (Diluted) | YoY change |
|---|---|---|---|
| FY2025 | 2025-12-31 | 44.26M | +15.5% |
| FY2024 | 2024-12-31 | 38.33M | -94.3% |
| FY2023 | 2023-12-31 | 673.62M | +2510.5% |
| FY2022 | 2022-12-31 | 25.8M | +0.0% |
| FY2021 | 2021-12-31 | 25.8M | — |
Weighted Avg Shares (Diluted) vs competitors
How KYTX compares with its peers on the latest reported figures
- KYTX's LTM Mar 2026 weighted avg shares (diluted) of 48.56M shares is the 8th highest of the 11 companies compared; the peer median is 72.78M shares.
- Its year-over-year change of +12.5% is the 6th highest of 10, against a peer median of +18.4%.
- Over three fiscal years its annual growth of +19.7% compares with a peer median of +13.5%.
| Company | Period | LTM | YoY | 3-year CAGR |
|---|---|---|---|---|
| LTM Mar 2026 | 225.47M | +9.3% | +15.5% | |
| LTM Mar 2026 | 159.92M | +5.1% | +9.7% | |
| LTM Mar 2026 | 94.61M | +90.6% | +51.6% | |
| LTM Mar 2026 | 90.28M | +9.3% | +8.9% | |
| LTM Mar 2026 | 80.03M | -5.4% | -0.7% | |
LXEOLexeo Therapeutics, Inc. Common Stock | LTM Mar 2026 | 65.52M | +98.2% | +28.7% |
| LTM Mar 2026 | 49.43M | +35.6% | +23.7% | |
| LTM Mar 2026 | 48.56M | +12.5% | +19.7% | |
| LTM Mar 2026 | 31.49M | — | +63.9% | |
CTNMContineum Therapeutics, Inc. Class A Common Stock | LTM Mar 2026 | 30.55M | +18.4% | +3.3% |
| LTM Mar 2026 | 18.01M | +34.2% | +11.4% | |
| Peer median (excluding KYTX) | 72.78M | +18.4% | +13.5% | |
Competitors are the stored peer set for KYTX. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.
Income Statement
Metric | FY2021 Dec 2021 | FY2022 Dec 2022 | FY2023 Dec 2023 | FY2024 Dec 2024 | FY2025 Dec 2025 |
|---|---|---|---|---|---|
| Revenue | 5.66M | 7.03M | 0 | 0 | 0 |
| Cost of Revenue | 0 | 0 | 1.71M | 2.13M | 0 |
| Gross Profit | 5.66M | 7.03M | (1.71M) | (2.13M) | 0 |
| Gross Margin | 100.0% | 100.0% | — | — | — |
| Research & Development | 25.85M | 28.4M | 48.22M | 112.47M | 133.72M |
| Selling, General & Admin | 6.15M | 8.01M | 12.48M | 30.13M | 36.11M |
| Operating Expenses | 32M | 36.41M | 60.7M | 140.47M | 169.83M |
| Depreciation & Amortization | 586K | 1.05M | 1.71M | 2.13M | 1.8M |
| EBITDA | (25.76M) | (27.78M) | (58.47M) | (125.2M) | (159.02M) |
| EBITDA Margin | -455.5% | -395.4% | — | — | — |
| Operating Income | (26.35M) | (29.38M) | (62.41M) | (142.6M) | (169.83M) |
| Operating Margin | -465.8% | -418.3% | — | — | — |
| Interest Income | 1K | 565K | 2.28M | 15.36M | 9.09M |
| Interest Expense | 3K | 65K | 187K | 142K | 489K |
| Other Income / Expenses | (4K) | 491K | 2.04M | 15.13M | 8.52M |
| Income Before Tax | (26.35M) | (28.89M) | (60.37M) | (127.48M) | (161.31M) |
| Pre-Tax Margin | -465.9% | -411.3% | — | — | — |
| Income Tax Expense | 0 | 0 | 0 | 0 | 0 |
| Net Income | (26.35M) | (28.89M) | (60.37M) | (127.48M) | (161.31M) |
| Net Margin | -465.9% | -411.3% | — | — | — |
| EPS (Basic) | (1.02) | (1.12) | (0.00) | (3.33) | (3.64) |
| EPS (Diluted) | (1.02) | (1.12) | (0.00) | (3.33) | (3.64) |
| Weighted Avg Shares | 25.8M | 25.8M | 673.62M | 38.33M | 44.26M |
| Weighted Avg Shares (Diluted) | 25.8M | 25.8M | 673.62M | 38.33M | 44.26M |
Kyverna Therapeutics, Inc.
NASDAQ:KYTX
Intrinsic Alpha fair value
Locked
Current Price
$4.48
Unlock the intrinsic value to see where the current price sits on the valuation runway.
Valuation runway
LockedGet the intrinsic value and margin of safety with a free account.
Continue the stock analysis
Jump to another research area for this company.